New hope for head & neck cancer patients after immunotherapy fails
Disease control
Recruiting now
This study is testing a new oral drug, NRC-2694-A, combined with a standard chemotherapy (paclitaxel) for adults with advanced head and neck cancer that has returned or spread. It is specifically for patients whose cancer continued to grow despite receiving modern immunotherapy d…
Phase: PHASE2 • Sponsor: NATCO Pharma Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC